Insulet (PODD) Tops Q2 EPS by 10c, Lowers FY Guidance

Insulet (NASDAQ: PODD) reported Q2 EPS of ($0.03), $0.10 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $124.26 million versus the consensus estimate of $132.86 million.

GUIDANCE:

Insulet sees Q3 2018 revenue of $144-151.5 million

Insulet sees FY 2018 revenue of $547-562 million, prior was for $565-580 million.

"The Company is raising its revenue expectations for U.S. Omnipod and Drug Delivery."

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c